March 2024

Artica Therapeutics Round

ARTICA THERAPEUTICS APPOINTS PIET WIGERINCK TO ITS BOARD OF DIRECTORS

Artica Therapeutics, Latest News /

LEIDEN, The Netherlands – March 21, 2024 – Artica Therapeutics B.V. (Artica), a biotechnology company developing a pipeline of covalent small molecules for autoimmune and inflammatory disorders, today announced that industry veteran Piet Wigerinck PhD is joining the board as an independent non-executive director. Dr Wigerinck is a seasoned executive with over three decades of […]

ARTICA THERAPEUTICS APPOINTS PIET WIGERINCK TO ITS BOARD OF DIRECTORS Read More »

Fusion Pharmaceuticals Logo

Fusion to be acquired by AstraZeneca for up to $2.4 billion.

Fusion, Latest News /

19 March 2024 – DUBLIN– We are pleased to announce that our portfolio company Fusion Pharmaceuticals Inc., (FUSN), is to be acquired for up to $2.4 billion by AstraZeneca. Fusion, is a clinical-stage biopharmaceutical company, headquartered in Toronto, with an office in Boston, developing next-generation targeted radiopharmaceuticals. These compounds combine the potent cancer cell killing

Fusion to be acquired by AstraZeneca for up to $2.4 billion. Read More »

Sybilla

Sibylla Biotech Enters a Strategic Collaboration

Latest News, Sibylla, Sibylla /

Sibylla Biotech Enters a Strategic Drug Discovery Collaboration with Ono Pharmaceutical in Central Nervous System Disorders   Milan, Italy, March 14, 2024 – Sibylla Biotech announced today a drug discovery collaboration with Ono Pharmaceutical Co., Ltd. (TSE: 4528) that will access Sibylla’s cutting-edge Pharmacological Protein Inactivation by Folding Intermediates Targeting (PPI-FIT) technology to identify and develop

Sibylla Biotech Enters a Strategic Collaboration Read More »

Endotronix 2

Endotronix Presents Positive PROACTIVE-HF Clinical Trial Results for its Cordella Pulmonary Artery Sensor.

Endotronix, Latest News /

Naperville, Illinois, USA.  5 March 2024.  Endotronix, Inc., a privately held company dedicated to advancing the treatment of heart failure (HF) at the intersection of digital health and medtech, presented 6-month results from its PROACTIVE-HF pivotal trial.  PROACTIVE-HF evaluated the company’s investigational Cordella Pulmonary Artery (PA) Sensor in New York Heart Association (NYHA) class III

Endotronix Presents Positive PROACTIVE-HF Clinical Trial Results for its Cordella Pulmonary Artery Sensor. Read More »

We use cookies and analytics to improve your online experience and to help us to understand where our audience is and how they reach us, as well as to understand what topics and site features are of greatest interest.  To find out more, please read our Privacy Policy. By clicking on the Accept button, you consent to our use of cookies and browsing analytics.

Scroll to Top